Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syra HealthSYRA +3.71%12 Debt-to-EBITDA is 0.08 as of Mar. 2026. GuruFocus rates SYRA with a GF Score™ of 12/100 and a GF Value™ of $0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 476 Healthcare Providers & Services companies, Syra Health ranks worse than 210083.82% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Syra Health's Debt-to-EBITDA or its related term are showing as below:
SYRA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -49.67 Med: -0.17 Max: -0.09
Current: -0.47
During the past 6 years, the highest Debt-to-EBITDA Ratio of Syra Health was -0.09. The lowest was -49.67. And the median was -0.17.
SYRA's Debt-to-EBITDA is ranked worse than 100% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.21
vs SYRA: -0.47
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Syra Health Debt-to-EBITDA Related Terms
Syra Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Syra Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYRA vs AMS, BMGL, BICX: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Syra Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syra Health Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syra Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Syra Health (SYRA) has a Debt-to-EBITDA of 0.08 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Syra Health. According to the industry distribution chart, Syra Health ranks #999999 out of 476 companies in the Healthcare Providers & Services industry.
Is Syra Health's Debt-to-EBITDA too high?
Syra Health's current Debt-to-EBITDA is 0.08. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.21. Syra Health's value of 0.08 is 96.4% below this industry median. Based on the distribution chart, Syra Health ranks #999999 out of 476 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Syra Health has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Syra Health's Debt-to-EBITDA compare to AMS and BMGL?
According to the Healthcare Providers & Services industry distribution chart, Syra Health ranks #999999 out of 476 companies for Debt-to-EBITDA. This places Syra Health in the lower half of its industry. The industry median Debt-to-EBITDA is 2.21. Syra Health's value of 0.08 is 96.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syra Health's current Debt-to-EBITDA of 0.08 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Syra Health. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syra Health's current Debt-to-EBITDA is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syra Health stock overvalued right now?
Based on GuruFocus' analysis, Syra Health (SYRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.73 — trading 230% above its estimated fair value. The current Debt-to-EBITDA is 0.08 and 96.4% below the Healthcare Providers & Services industry median of 2.21. Syra Health's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Syra Health (SYRA), the current Debt-to-EBITDA is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syra Health (SYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Syra Health stock appears to be overvalued.
The current stock price of $0.73 is trading 230% above its estimated GF Value™ of $0.22.
GuruFocus considers Syra Health to be Significantly Overvalued.
Key valuation signals for SYRA:
Debt-to-EBITDA: 0.08
GF Value™: $0.22 vs. price of $0.73 (230% above fair value)
Industry Position: 96.4% below the Healthcare Providers & Services median (#999999 of 476)
No single metric tells the full story. See the SYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations. It delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. The various services offered by the company include Syrenity, a mental health application providing preventative care and interventions for behavioral and mental health conditions; SyraBot, a chatbot offering members access to necessary information via the firm's AI-powered customer support chat system; CarePlus, an electronic medical records solution designed for small to mid-sized healthcare organizations; and patient engagement and education services, among others.
12GF Score
Get the complete analysis for SYRA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRA has been successfully added to your 
